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The  recent  use  of  chemically defined polypeptides to  investigate immunological 
phenomena has resulted in a  wealth of information regarding the chemical and bio- 
logical basis of antigenicity, immunogenicity, skin reactivity, and cell-antigen interac- 
tions. Information obtained from chemically defined systems is more meaningful and 
comprehensive than that obtained from the chemically ill-defined systems previously 
used,  in  that  these  systems lend themselves more  readily to  specific experimental 
manipulation.  In  these  respects peptides and proteins of  known  amino acid  se- 
quence and/or  stucture  offer  excellent immunochemical  tools.  Studies utilizing 
these systems have been recently reviewed (1-4). 
Immunochemical  studies  on  one  well-characterized protein,  namely  the  tobacco 
mosaic virus protein (TMVP), which were conducted during the past several years, 
resulted in the isolation, characterization, and synthesis of a major antigenic determi- 
nant of the protein, and in the understanding of several of the principles underlying 
the binding of the determinant with antibodies. An eicosapeptide, representing residues 
93-112  of  the  protein and  having  the  amino  acid sequence  Ileu-Ileu-Glu-Val-Glu- 
AspNH2-GluNH2-Ala-AspNH2-Pro-Thr-Thr-Ala-  Glu-Thr-Leu-Asp-Ala-Thr-Arg, was 
found to bind specifically  with antibodies produced by rabbits in response to immuni- 
zation with TMVP (5, 6). Subsequent work demonstrated that anti-TMVP antibodies 
also bound with the C-terminal decapeptide portion of the eicosapeptide (7). Although 
antibodies capable of binding with the C-terminal di-, tri-, or tetrapeptide could not be 
demonstrated,  some rabbits produced antibodies which bound with  the  C-terminal 
pentapeptide, while others produced antibodies which required the C-terminal hexa- 
or heptapeptide for demonstrable binding (8, 9). However, antibodies produced by all 
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rabbits tested were shown to bind specifically with the N-octanoylated C-terminal 
tripeptide, namely with N-octanoyl-Ala-Thr-Arg (10).  Similarly, studies with anti- 
TMVP  antibodies produced by guinea pigs demonstrated specific binding with the 
eicosapeptide and its C-terminal decapeptide. Binding between the C-terminal penta- 
peptide and pooled globulins obtained from TMVP-sensitized guinea pigs was also 
shown. 1 
The work on the immunochemistry of the TMVP peptides was hitherto aimed 
primarily at elucidating the principles underlying the binding of the determinant 
with antibodies to the protein. In view of the findings described, it was apparent 
that the use of this well-characterized system would serve as a powerful tool for 
the investigation of cellular immune responses as well. The present communi- 
cation reports results of experiments dealing with  the immunogenicity of the 
peptides, with their ability to elicit skin reactions in TMVP-sensitized animals, 
with their capacity to stimulate DNA synthesis in lymphocytes derived from 
TMVP-sensitized  animals,  and  with  their  ability to  inhibit the migration  of 
peritoneal exudate cells derived from such animals. 
Materials  and  Methods 
Tobacco Mosaic  Virus Protein  (TMVP).--The  protein was generously  supplied  by Dr. 
C. A. Knight, Virus Laboratory, University of California, Berkeley, Calif. TMVP was prepared 
from the virus as described by Fraenkel-Conrat (11). 
TMVP Peptides2.--The  eicosapeptide representing residues 93-112 of TMVP was obtained 
from a tryptic digest of the protein as previously described  (12, 5). All other peptides were 
synthesized by the Merrifield solid phase peptide synthesis method (13) as described (7, 8, 14). 
The deca- and pentapeptides were purified and analyzed as previously described (7, 8). Results 
of amino acid analyses are given in Table I. 
(Lys)n pentapeptides were synthesized  by the sequential coupling of lysine residues onto 
the pentapeptide-resin using t-Boc-N-e carbobenzyloxy-L-lysine  (obtained  from  Fox Chem- 
ical Co., Los Angeles, Calif.). Mter 6 and 10 lysine couplings, the cleaved peptides contained 
an average of only 4.26 and 7.18 lysifie residues, respectively (Table I). Electrophoresis  of 
these crude peptides performed  at pH  6.4  revealed  the presence  of  several  lysylpeptides, 
showing that these peptides were heterogeneous with respect to lysine residues. For conven- 
ience, the synthesized peptldes are designated as (Lys)4 pentapeptide and (Lys) ~  pentapeptide. 
The N-acyl-Ala-Thr-Arg  derivatives were prepared by solid phase synthesis in a manner 
similar to  the preparation of N-octanoyl-Ala-Thr-Arg previously described  (15). Butyric, 
hexanoic,  octanoic, and decanoic acids (99-100%  pure, obtained from Sigma Chemical Co., 
St. Louis, Mo.) were coupled to the tripeptide-resin using 4 moles fatty acid and 4 moles of 
dicyclohexylcarbodiimide  per mole of peptide, The acylpeptides were cleaved from the resin 
with HBr-trifluoroacetic acid, dissolved in a mixture of methanol:water:  acetic acid (50:40 :- 
10), and reduced overnight  by catalytic hydrogenation at atmospheric pressure  as described 
(14). The acylpeptides were electrophoresed  at pH 6.4. Ninhydrin and Sakaguchi  staining 
1 Benjamini, E. Unpublished  results. 
2 The approximate mol wts of the antigens utilized in these studies are as follows: TMVP, 
17,000;  eicosapeptide,  2184; decapeptide,  1077; pentapeptide,  574; (Lys)~ pentapeptide, 
1470; (Lys)4  pentapeptide, 1086; butyryl-tripeptide,  416; hexanoyl-tripeptide, 444; octanoyl- 
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revealed that  Sakaguchi positive peptides were ninhydrin negative and neutral,  indicating 
complete N  acylation. The amino acid analyses of the N-acyl-Ala-Thr-Arg peptides are given 
in Table I. 
Radioiodinated  TMVP.--Approximately  1 mg protein was iodinated with 2  mCi  (125I)- 
NaI in 0.1 N NaOH (obtained from New England Nuclear Corp., Boston, Mass.) according to 
the procedure described by  Greenwood et  al.  (16). The  (125I) TMVP was recovered after 
passage through a  G-25 Sephadex column (1.5 X  75 cm) equilibrated and eluted with 0.1 
NaHCO,. The radioiodinated protein had a specific activity of 1 X  10 6 cpm/#g. For antibody 
assay, it was diluted with 100-fold excess of noniodinated TMVP in 0.1 M NaHCO3 containing 
1% bovine serum albumin (BSA) obtain from Pentax Inc., Kankakee, Ill. 
Immunlzation.--Male and female guinea pigs weighing approximately 350 g were immu- 
nized with TMVP, with peptides, or with BSA in  borate-buffered saline,  pH 8,  emulsified 
TABLE I 
Amino Acid Analysis of TMVP Peptides* 
Peptide 
Molar ratio 
Lys  Arg  Asp  Thr  Glu  Pro  Ala  Val  Ileu  Leu 
Ileu-Ileu-  Glu-Val-Glu-  1.04  2.99  3.78 
AspNH2-GluNH2-Ala- 
AspNH2-Pro-Thr-Thr-Ala- 
Glu-Thr-Leu-Asp-Ala-Thr- 
Arg (eicosapeptide) 
Thr-Thr-Ala-  Glu-Thr-Leu-  0.90  1.03  3.93 
Asp-Ala-Thr-Arg  (decapep- 
tide) 
Leu-Asp-Ala-Thr-Arg  (penta-  1.02  0.98  1.00 
peptide) 
(Lys)  4-pentapeptide  4.26  0.88  0.96  0.97 
(Lys)7-pentapeptide  7.18  0.92  0.99  1.02 
Butyryl-Ala-Thr-Arg  1.16  N.D. 
Hexanoyl-Ala-Thr-Arg  0.95  1.01 
Octanoyl-Ala-Thr-Arg  0.93  1.05 
Decanoyl-Ala-Thr-Arg  0.96  1.00 
4.03  1.10  2.96  1.04  0.88  1.01 
1.06  2. I1 
1. O0 
1.08 
1.02 
0.84 
1.03 
1.02 
1.04 
1.00 
0.99 
1.00 
0.97 
*The peptides were hydrolyzed under  open reflux at  ll0°C  for 24 hr and quantitative 
amino acid  analyses performed using the  Spinco Model  120B amino acid  analyzer. 
with an equal volume of Freund's complete adjuvant containing Mycobacterium butyricum 
(Dffco Laboratories, Inc., Detroit, Mich.). Injections consisted of 0.1 ml administered intra- 
dermally into each footpad, 0.3  ml administered intramuscularly, and 0.3  ml given subcu- 
taneously. Animals were sensitized to TMVP with a total dose of 0.15 #mole (2.5 mg). Animals 
sensitized with BSA were given a  total antigen dose of 0.038 #mole (2.5 mg). Doses of the 
peptides injected ranged from 0.05 #mole to 7.5 #mole. The animals were bled for antibody 
studies 1 month after the immunizations and were skin tested immediately thereafter. For 
studies of lymphocyte stimulation and capillary migration, animals were used  1-2  months 
after immunization. 
Skin Tests.--Skin tests were performed on a shaved area of the flank by intradermal injec- 
tions of 0.1 ml of antigen in borate-buffered saline, pH 8. Skin reactions were recorded at the 
end of 1 hr (immediate reactions) and 24 hr (delayed reactions) after the challenge. Reactions 
were considered positive if they consisted of erythema and induration of 5 mm or greater. 
Antibody Determination.--The  test antiserum was reacted with (125I)TMVP and the com- 
plexes precipitated overnight in the cold by rabbit anti-gulnea pig serum. Radioactivity was 136  IMMUNE  RESPONSE  TO  ANTIGENIC  DETERMINANT  OF  TMVI  ~ 
measured in the supernatant using the Model 1810 radiation analyzer and Model D5  (203V) 
well scintillation detector (Nuclear-Chicago Corp., Des Plaines, Ilk). 
Lymphocyte Stimulation.--Splenic lymphocytes were cultured according to the method of 
Dutton and Eady (17) ; I0 X  106 cells were cultured in 4 ml of Eagle's minimal essential me- 
dium for suspended cultures (Spinner's medium, obtained from Grand Island Biological Co., 
Grand Island, N. Y.),  containing 100 units of penicillin and 100 #g of streptomycin per ml, 
1% L-glutamine, and 15% calf serum. All cultures were prepared in duplicate or triplicate. 
Antigen was added in 0.1  ml saline at the beginning of the culture, and the mixtures were 
incubated at 37°C  in an atmosphere of 5% CO2 and 95% air for 2 days, at the end of which 
period 0.1 ~Ci of 2 14C-thymidine (specific activity, 59.2 mCi/mole, obtained from New England 
Nuclear Corp.)  was introduced into each culture tube. The cells were harvested in the cold 
24 hr later by serially suspending them once in saline, twice in 5% trichloroacetic acid,  and 
once in methanol. The precipitate was dissolved by incubation in 1 ml of Hyamine at 56°C 
for 1 hr, transferred to counting vials,  and prepared for scintillation counting by adding  12 
ml of Omnifluor (New England Nuclear Corp.) in toluene (4 g Omnifluor in 1 liter toluene). 
The radioactivity was measured on the Nuclear-Chicago Mark I  liquid scintillation counter. 
The variation between replicate tubes was not more than ±10c/~. 
Capillary Migration.--Capillary migration was performed  as  described  by David  et  al. 
(18). Peritoneal exudates were induced in guinea pigs by the intraperitoneal injection of 30 
ml light mineral oil  (Marcol, Esso Humble Oil and Refining Co., Houston,  Texas).  3  days 
later the cells were harvested by washing the peritoneal cavity with 200 ml of Hanks' solution. 
The packed ceils were suspended in Spinner's medium, 7.5% by volume, and capillary tubes 
filled with the cell suspension. The tubes were sealed and spun in the cold for 5 min at 900 
rpm. They were cut at the cell-fluid interface and placed in Mackaness-type culture chambers, 
two tubes per chamber. All chambers were prepared in duplicate. The chambers were filled 
with Spinner's medium containing 100 units of penicillin and 100 #g of streptomycin per ml, 
1% L-glutamine, 15% normal guinea pig serum, and various concentrations of the test anti- 
gen. They were then sealed and incubated for 24 hr at 37°C. The cell image was projected and 
traced,  and the area of migration measured using a  planimeter. The areas of migration in 
duplicate test chambers (four tubes) were averaged, and the results were expressed as per cent 
of migration of peritoneal cells in the control chambers containing no antigen. 
RESIY]LTS 
Immunogenicity.--Groups of guinea pigs were injected with 0.05, 0.5, or 5.0 
/~moles of octanoyl tripeptide, with 0.05, 0.5, or 7.5/~moles of pentapeptide,  or 
with 0.05,  0.5,  or 2.5  ~moles  of decapeptide  in complete Freund's  adjuvant. 
These injections did not elicit skin sensitization, antibody formation, or lympho- 
cyte sensitization. 
Peptide-injected animals were skin tested with 6 m/~moles TMVP and did not 
demonstrate  either immediate or delayed  skin reactivity  (Table II),  whereas 
control animals immunized with 0.15  #moles TMVP  had positive immediate 
and delayed reactions to TMVP.  Animals immunized with 0.038 #moles BSA 
did not react to challenges given with TMVP, nor did the TMPV or peptide- 
injected animals react to challenges given with 1.5 m~mole BSA. 
Individual sera obtained from the peptide-injected animals were titered with 
(125I)TMVP.  Results  showed that  antibodies  capable of binding with TMVP 
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animals produced antibodies capable of binding the antigen (Fig. 1). The specific- 
ity of this reaction was confirmed with (l~5I)lysozyme. 
Animals which were injected with each peptide and TMVP-sensitized ani- 
mals which had not been  used  for skin  tests  were  sacrificed.  Their  splenic 
TABLE  II 
Skin Reactions to TMVP in Guinea Pigs Injected With TMVP  or With Antigenic Peptides 
of TM VP 
Antigen  injected  Dose injected 
Skin reactions 
Immediate (1 hr)  Delayed  (24 hr) 
Decapeptide 
~mole 
0.05  0/3*  0/3 
0.5  0/4  0/4 
2.5  0/4  0/4 
Pentapeptide  0.05  0/4  0/4 
0.5  0/3  0/3 
7.5  0/4  0/4 
Octanoyl-tripeptide  0.05  0/4  0/4 
0.5  0/4  0/4 
5.0  0/12  0/12 
TMVP  o. 15  5/5  5/5 
* Number of animals showing positive reactions/number  of animals tested with 6 re#mole 
TMVP. 
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FIO. 1.  Average binding of 125I-TMVP by sera of guinea pigs injected with TMVP (Q), 
with pentapeptide  (C)), with decapeptide (A) or with octanoyl-tripeptide  (X). The amount 
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lymphocytes were cultured with TMVP in a dose range of 0.75-750 ##mole/ml, 
and  stimulation  of DNA  synthesis  was  measured  by  incorporation  of  Q4C)- 
thyrnidine.  Whereas the TMVP  stimulated  thymidine uptake  in lymphocytes 
TABLE III 
In  Vitro  14C-Thymidine  Incorporation  in Response  to TMVP in Spleen  Cdl Cultures  Derived 
From TMVP and Peptide Injected Guinea  Pigs 
Antigen injected  Dose injected  Stimulation* 
I.*mole 
Decapeptide  2.5  1.0  (2) 
Pentapeptide  7.5  1.7  (1) 
Octanoyl-tripeptide  5.0  1.0  (2) 
TMVP  0.15  4.3  (2) 
* Ratio of 14C-thymidine incorporation  in cultures  with  750 /z#mole/ml TMVP relative 
to incorporation  in control cultures, from the same guinea pig, without TMVP. 
:~ Parentheses indicate number of animals tested. 
TABLE IV 
Skin  Reactions  in Guinea  Pigs Immunized  with  TMVP 
Challenging antigen  Test dose 
Skin reactions 
Immediate  (1 hr)  Delayed (24 hr) 
ml~mote 
TMVP  6  6/9*  9/9 
O. 6  5/9  6/9 
(Lys)7 pentapeptide  750  1/4  2/5 
75  2/9  1/9 
(Lys) 4 pentapeptide  700  5/9  6/9 
70  0/9  1/9 
Decapeptide  320  2/9  2/9 
Pentapeptide  1500  3/9  2/4 
150  3/9  4/9 
Hexanoyl-tripeptide  1000  0/9  3/9 
Butyryl-tripeptide  1000  6/9  3/4 
BSA  1.5  0/9  1/9 
PPD  10 #g  0/9  9/9 
* Number of animals showing positive reactions/number  of animals tested. 
derived  from  TMVP-sensitized  animals,  the  lymphocytes  derived  from  the 
animals injected with the peptides were not significantly stimulated (Table III). 
Skin  Reactions.--In  order  to determine  the  ability  of the  peptides  to elicit 
skin  reactions,  guinea  pigs  were  immunized  with  TMVP,  and  subsequently 
skin tested with TMVP and the TMVP peptides. Preliminary results indicated 
that low test doses of the peptides  (in the range of 0.05 #moles)  did not elicit 
skin reactions. At higher concentrations, however,  all of the peptides listed Jn SPITLER,  BENJAMINI,  YOUNG~ KAPLAN,  AND  FUDENBERG  139 
Table  IV  elicited specific delayed reactions in  at  least  some  of  the  animals 
(Table IV). Delayed reactions were always elicited by PPD,  since all the ani- 
mals were injected with Freund's complete adjuvant. In addition to the delayed 
TABLE V 
In  Vitro 14C-Thymidine Incorporation in Response to TMVP Peptides in Spleen Cell Cutures 
Derived from  TMVP  Sensitized  Guinea  Pigs 
Average stimulation at 
Antigen  Dose range  highest concentration* 
ml,  zmole/ml 
TMVP  0.00075-0.75  4.8  (7):~ 
Pentapeptide  0.04-400  1.5  (2) 
Decapeptide  1.6-160  0.84  (1) 
Oetanoyl-tripeptide  0.250-250  1.1  (3) 
Eicosapeptide  1.7-250  1.2  (4) 
* Ratio of 14C-thymidine incorporation in cultures with antigen present relative to 14C- 
thymidine incorporation in control cultures, from the same guinea pig, without antigen. 
:~ Number of animals tested. 
TABLE VI 
Effect of TMVP  and  TMVP Peptides on the Migration of Peritoneal Exudate Cells  Derized 
From Guinea Pigs Immunized With TM VP or Tuberculin 
Antigen  Concentration in 
chamber 
Migration* 
TMVP  PPD 
sensitive cells  sensitive cells 
#mole/ml  %  % 
TMVP  0.006  58  107 
TMVP  0.003  53  83 
TMVP  0.0006  47  96 
Pentapeptide  0.5  40  109 
Decapeptide  1.0  37  138 
(Lys) 4-pentapeptide  1.0  47  82 
Butryl-tripeptide  1.0  50  87 
Hexanoyl-tripeptide  1.0  45  111 
Hexanoyl-tripeptide  0.5  69  136 
Octanoyl-tripeptide  1.0  42  100 
Octanoyl-tripeptide  0.5  84  87 
Decanoyl-tripeptide  1.0  61  93 
PPD  15 #g  14  29 
* Numbers represent per cent migration in experimental chambers (compared  to that in 
control chambers incubated without antigen). 
reactions, all of these peptides, except the hexanoyl-tripeptide, elicited specific 
immediate reactions in some of the test animals. The specificity of the delayed 
and  the immediate reactions was  confirmed by the fact that guinea pigs sen- 140  IMMUNE  RESPONSE  TO  ANTIGENIC  DETERMINANT  OF  TMVP 
sitized  to  BSA  and  challenged  with  the  peptides  did  not  demonstrate  skin 
reactions when they were tested with the peptides in the same concentrations 
as  those  used  to  elicit  reactions  in  TMVP-sensitized  animals.  Positive  skin 
FIC. 2.  Effect of TMVP and peptides on the migration of peritoneal exudate cells derived 
from guinea pigs immunized with TMVP  or tuberculin. 
tests  were  obtained  with  1  #mole  of  the  octanoyl-  and  decanoyl-tripeptide; 
however,  these  reactions  were  considered  nonspecific  since  similar  reactions 
were also elicited in BSA-sensitized guinea pigs. 
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mals were cultured with TMVP or the TMVP peptides in order to determine 
whether or not the peptides could stimulate the incorporation of (1*C)thymi- 
dine by these cells.  Both TMVP and the peptides were tested in a wide range 
of concentrations. The results show that whereas TMVP caused lymphocyte 
stimulation, the peptides did not significantly stimulate at any of the concen- 
FIG. 3.  Effect of TMVP peptides and PPD  on the migration of peritoneal exudate cells 
derived from guinea pigs immunized with TMVP  or tuberculin. 
trations  tested.  Data  for the  stimulation  in  cultures  containing  the  highest 
antigen concentration are given in Table V. The specificity of stimulation by 
TMVP was demonstrated by the fact that TMVP in the range of concentra- 
tions tested failed to stimulate splenic lymphocytes derived from BSA-sensi- 
tized guinea pigs, and by the fact that BSA, at a wide range of concentrations, 
did not stimulate TMVP-sensitized lymphocytes. 
Inhibition  of Capillary Migration.--Results  given  in  Table  VI  show  that 
the capillary migration of peritoneal exudate cells derived from TMVP-sensi- 142  IMMUNE  RESPONSE  TO  ANTIGENIC  DETERMINANT  OF  TMVP 
tized guinea pigs was  specifically inhibited by TMVP,  by the  pentapeptide, 
by the decapeptide, by the (Lys)4 pentapeptide, and by the N-acyl-tripeptides. 
At  the  same  concentrations,  these  antigens  did  not  significantly inhibit  the 
migration of the peritoneal exudate cells derived from tuberculin-sensitive ani- 
mals.  Results given are the  averages of two experiments. As  expected, PPD 
was inhibitory since both the TMVP and BSA were injected in Freund's com- 
plete  adjuvant.  Representative  results  of  the  inhibition  of migration  are  il- 
lustrated in Figs. 2 and 3. 
DISCUSSION 
Data presented in this communication show that the antigenic peptides of 
TMVP  (i.e., those capable of combining with anti-TMVP)  are non immuno- 
genic. This is evident from the findings that animals which were injected with 
the peptides in a wide range of doses failed to produce skin reactions to intra- 
dermal injections of TMVP, nor did they produce antibodies capable of react- 
ing with (125I)TMVP. Further, splenic lymphocytes derived from these animals 
could not be stimulated by TMVP. 
It  should  be noted  that  the  test  animals  were  challenged with  the  whole 
antigen, TMVP, rather than with the injected peptides. Previous work on the 
binding  of TMVP  peptides  with  antibodies  showed  that  the  binding  of the 
determinant with  antibodies increases with increase  in  the length  of peptide 
chain (9). It was therefore felt that the chances for the detection of an immune 
response to the peptides would be increased by using  the whole antigen rather 
than the peptides for testing. 
There is no clear cut minimum size requirement for a compound containing 
an antigenic determinant to be able to induce the immune response. It is gen- 
erally accepted that  antigens  of relatively high molecular weight are usually 
immunogenic. Many compounds of low molecular weight are nonimmunogenic 
or  are  immunogenic only when  coupled to  a  larger  molecule. However, the 
immunogenicity of compounds of tool wt of approximately 5000 or below has 
been reported (19-24). Two such compounds, ce,N-DNP-hepta-L-Lysine, and 
a p-azo-benzenearsonate conjugate of hexa-L-tyrosine, which were found to be 
immunogenic (22,  23), have approximately the same molecular weight as that 
of the  decapeptide which  we  found was  not  immunogenic although  it  does 
combine with anti-TMVP. It thus appears that the molecular weight necessary 
for immunogenicity may vary from system to system and is probably governed 
by the chemical nature of the determinant and/or the carrier. 
The data presented herein show that the TMVP peptides and their deriva- 
tives elicited specific delayed and immediate skin reactions in guinea pigs im- 
munized with  TMVP.  It should be noted that  the  concentration of TMVP 
peptides necessary to obtain a response was high when compared to the con- 
centration  of  the  whole  antigen,  TMVP,  required.  However,  the  responses 
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why only high challenging dosages of peptides elicited responses. Perhaps it is 
because binding of the peptides with humoral antibodies or with cellular re- 
ceptors is low. Perhaps it is because at high concentrations the peptides aggre- 
gate, thus forming multivalent antigens. Also, high concentrations may enhance 
the adsorption of the peptides onto body proteins, thus forming either multi- 
valent antigens or univalent antigens of large molecular weight with increased 
binding.  It need not be  assumed, however,  that  the high concentrations of 
peptides  required  indicates  that  aggregation with  formation of multivalent 
antigens must occur for a skin reaction to appear. The necessity for using high 
concentrations of the peptides in our studies may also be due to the more rapid 
removal of small peptides from the injection site than when high molecular 
weight antigens are used. 
The delayed hypersensitivity skin reactions which were elicited by the pep- 
tides were independent of carrier specificity. Delayed reactions were elicited 
with all of the peptides tested, but the lack of carrier specificity is most apparent 
in the ability of the N-acyl derivatives of the tripeptide to elicit reactions. The 
tripeptide Ala-Thr-Arg may, in this case, be considered the antigenic determi- 
nant or hapten. It may, however, be argued that even in this small peptide, 
one or two of the C-terminal amino acids may still constitute a portion of the 
carrier. Although this can not yet be excluded, it is rather unlikely since it has 
been  shown  (15)  that  octanoyl-Thr-Arg  does  not  bind  with  antibodies  to 
TMVP. It is generally accepted that the elicitation of delayed skin hypersen- 
sitivity reactions requires carrier specificity in contrast to immediate reactions 
which can be elicited equally well with many hapten-carrier conjugates (25-30). 
However,  in  some  of  the  studies  cited,  delayed reactions  could be  elicited 
by the immunizing hapten conjugated to a carrier different from that used in 
the primary immunization if high antigen concentrations were used. This ob- 
servation correlates with our findings that elicitation of delayed skin reactions, 
independent of carrier specificity, required high antigen dosages. An apparent 
absence of carrier specificity has been demonstrated by Leskowitz (24)  using 
polytyrosine-p-azo benzenearsonate conjugates for immunization. 
The  results  obtained in  experiments  dealing with  the  stimulation of 14C- 
thymidine incorporation into spleen cells derived from TMVP-sensitized guinea 
pigs show that whereas TMVP was capable of stimulation, none of the peptides 
tested were stimulatory. It should be noted that the peptides were used in a 
wide range of concentrations, adjusted so that they approximately overlapped 
the concentrations of TMVP both on a weight basis and on a molar basis. 
In some studies lymphocyte stimulation was produced by the immunizing 
hapten-protein conjugates, while the hapten conjugated to an unrelated carrier 
was ineffective (31, 32), indicating that carrier specificity plays a role in in vitro 
lymphocyte stimulation as well as in the in vivo response. Therefore, the lack 
of carrier specificity may account for the failure of the TMVP peptides to cause 
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for stimulation, then it must be postulated that even the eicosapeptide either 
contains only part of the carrier (not sufficient to participate in stimulation) 
or that the carrier consists of other portions of the protein. However, others 
have shown that lymphocyte stimulation can be produced by a hapten conju- 
gated to a protein different from that used in immunization (30). 
The inability of the TMVP peptides to stimulate may be due to the possi- 
bility that even the relatively high concentrations of peptides which were in 
some of the cultures were not high enough to induce stimulation. Perhaps the 
binding of the peptides to receptor sites on the cells is so low that even these 
concentrations were insufficient. However, when the concentrations were in- 
creased  10-100-fold,  the stimulation was not increased but rather decreased, 
probably due to cytotoxicity. A further possible explanation for the inability 
of the peptides  to  stimulate lymphocyte proliferation is  that  a  multivalent 
antigen may be required. 
Stulborg  and  Schlossman reported  that  only immunogenic members  of  a 
homologous series of a, DNP-z-lysines were capable of stimulation of sensitized 
lymphocytes (33). The results obtained with the TMVP peptides are in accord 
with these findings in that the TMVP peptides are nonimmunogenic, neither 
are they capable of stimulating TMVP-primed lymphoeytes. 
Although the peptides were not able to stimulate primed lymphocytes, they 
were  able  to  elicit  delayed skin  reactions  in  TMVP-sensitized  guinea pigs. 
These results differ from those described by several authors in which a direct 
correlation between the ability to stimulate primed lymphocytes and the abil- 
ity to elicit delayed skin reactions has been noted (22, 33, 34). 
Results reported in this communication further show that the TMVP pep- 
tides  specifically inhibit  the  capillary migration  of  peritoneal  exudate  cells 
derived from TMVP-sensitized guinea pigs. These findings are in agreement 
with reports by others noting the correlation between delayed reactions and 
inhibition of capillary migration (18, 35, 36). In contrast to findings previously 
reported (37),  the results reported herein demonstrate that carrier specificity 
is not essential for the inhibition of capillary migration. In fact, our finding 
that carrier specificity is not essential for inhibition of migration is in complete 
agreement with  our  demonstration of  the  lack  of carrier  specificity for  the 
elicitation of delayed skin reactions. 
The present results show that the peptides were capable of inhibiting capil- 
lary migration of sensitized peritoneal exudate cells,  although they were not 
immunogenic. These findings contrast with those previously reported which 
correlated the ability to inhibit with immunogenicity (35). The results further 
show that although the peptides could inhibit capillary migration, they were 
unable to stimulate TMVP-primed lymphocytes. A similar lack of correlation 
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ture filtrate  elicited  delayed skin  reactions  in  BCG-sensitized  animals  (38), 
inhibited the capillary migration of peritoneal exudate cells derived from these 
animals (36), but failed to stimulate BCG-primed lymphocytes2 These obser- 
vations differ from those reported by others who showed that  the ability to 
inhibit capillary migration correlated with  the ability to stimulate sensitized 
lymphocytes (33, 35). 
In  some  respects  our findings  on  the  various  parameters  of  the  immune 
response tested with the TMVP system agree with those reported by others 
utilizing different systems, and in some respects they do not. The disagreements 
may well stem from the fact that  the antigenic systems vary. However, the 
use of many well characterized antigenic systems is required in order to eluci- 
date the common underlying principles governing the immune response. 
SUMMARY 
The following peptides have previously been shown to bind specifically with 
antibodies  to  TMVP:  (a)  An  eicosapeptide  representing  residues  93-112  of 
TMVP and having the sequence Ileu-Ileu-Glu-Val-Glu-AspNH2-GluNH2-Ala- 
AspNH2-Pro-Thr-Thr-Ala-Glu-Thr-Leu-Asp-Ala-Thr-Arg.  (b)  Its  C-terminal 
decapeptide.  (c)  Its  C-terminal pentapeptide.  (d)  N-octanoyl-C-terminal-tri- 
peptide.  (e)  (Lys)4-C-terminal-pentapeptide.  (f)  (Lys)~ C-terminal-pentapep- 
tide.  The present communication deals with  the investigation of several pa- 
rameters of the immunological activity of the peptides. The results show that 
none of the peptides  tested were immunogenic in guinea pigs,  nor did  they 
stimulate  the  incorporation  of  14C-thymidine  by  spleen  cells  derived  from 
TMVP-primed  animals.  Results  also  showed  that  all  of the peptides  tested 
could elicit specific delayed and immediate skin reactions in TMVP-sensitized 
guinea pigs,  and furthermore, that  the peptides could specifically inhibit the 
migration of peritoneal exudate cells derived from these animals.  The elicita- 
tion of delayed skin reactions and the ability to inhibit migration of peritoneal 
exudate cells were independent of carrier specificity. 
We thank Mrs. Christine von Muller and Mr. Robert Ripley for their excellent  technical 
assistance in some of the studies. 
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